Overview of completed/ongoing phase 3 clinical trials involving dabigatran
| . | Comparator . | No. (approximate) of patients . | Results expected/published . | Acronym . |
|---|---|---|---|---|
| AF | VKA | 18 000 | 200911 | RELY |
| VTE primary prophylaxis, orthopedic | LMWH | 7 500 | 2007-20098-10 | RE-NOVATE, RE-MOBILIZE, RE-MODEL |
| VTE acute treatment | VKA (patients will have LMWH therapy during the first week of therapy with dabigatran or VKA) | 2 600 | 2011, 2012 | RECOVER |
| VTE secondary prevention | Placebo (before randomization, all patients have received 6-18 months of anticoagulation) | 4 500 | 2011 | REMEDY, RECOVER II |
| . | Comparator . | No. (approximate) of patients . | Results expected/published . | Acronym . |
|---|---|---|---|---|
| AF | VKA | 18 000 | 200911 | RELY |
| VTE primary prophylaxis, orthopedic | LMWH | 7 500 | 2007-20098-10 | RE-NOVATE, RE-MOBILIZE, RE-MODEL |
| VTE acute treatment | VKA (patients will have LMWH therapy during the first week of therapy with dabigatran or VKA) | 2 600 | 2011, 2012 | RECOVER |
| VTE secondary prevention | Placebo (before randomization, all patients have received 6-18 months of anticoagulation) | 4 500 | 2011 | REMEDY, RECOVER II |